

***Pharmaceutical Patent Analyst* and *Journal of Comparative Effectiveness Research* accepted for coverage by MEDLINE**

Future Science Group Ltd has today announced that *Pharmaceutical Patent Analyst* (ISSN 2046-8954) and *Journal of Comparative Effectiveness Research* (ISSN 2042-6305) have been selected for coverage by **MEDLINE®**.

Maintained by the US National Library of Medicine, MEDLINE® (Medical Literature Analysis and Retrieval System Online) is a premier bibliographic database containing approximately 13 million references to journal articles in the life sciences.

Pharmaceutical Patent Analyst is published 6 issues per year in print and online formats on a rapid publication basis, with articles subject to peer review by three independent assessors. The journal has an international expert authorship and offers scientific analysis of recent developments in the patent literature, and commentary on IP law issues affecting research and development. Coverage of the journal is overseen by three Senior Editors and an extensive international advisory panel.

The three Senior Editors are **Dr Lyn Jones, Pfizer (USA), Dr Andrew McKnight, AnaptysBio (USA) and Professor David Rotella, Montclair State University (USA)**.

Senior Editor **David Rotella** said, “*Pharmaceutical Patent Analyst* has rapidly and successfully filled a void in the literature”. **Lyn Jones** added, “Acceptance for coverage is yet further recognition of the high-quality content published in the journal”.

The *Journal of Comparative Effectiveness Research* is also a bimonthly publication, maintaining the rigorous publication standards of all Future Science Group journals. CER, or patient-centred outcomes research, draws from the disciplines of health technology assessment, outcomes research, clinical epidemiology and implementation science, among others, to better answer the fundamental question ‘which treatment will work best, in which patient, and under what circumstances?’ Calls for more patient-centred care have substantially increased the need for, and support of, research evidence that can assist patients, physicians, payers and policymakers in making ‘real-world’ choices among available treatments. The **JCER** provides stakeholders with the information they need to make informed and specific decisions on clinical practice. The journal content is shaped by two Senior Editors, **Sheldon Greenfield (University of California, Irvine, USA)** and **Eugene C Rich (Mathematica Policy Research, USA)**, a team of six Associate Editors and international Editorial Board representing the diverse stakeholders in this topic.

Senior Editor **Eugene Rich** said, "As we noted in the January 2012 inaugural issue, JCER aims to provide a rapid-publication platform for the presentation of methodological advances and new research findings, as well as policy issues and commentaries, relevant to comparative effectiveness and patient-centred outcomes research, and we are delighted with how the journal has progressed to date. With JCER articles now readily found through indexing resources such as Medline, the journal can better provide the various stakeholders with key data and insights to promote use of information on comparative effectiveness".

Senior Editor **Sheldon Greenfield** added, "This is an important step forward for JCER and furthers our aim to become the definitive source of information for all those interested in comparative effectiveness research. The increased discoverability of JCER articles through Medline will add to the dissemination of this important information, which is vital to the current health care agenda."

Elisa Manzotti, Publisher of the **Future Science Group** journals commented, "*We are delighted that these journals have been accepted for inclusion and we will work with the Senior Editors to ensure that future issues keep pace with the huge amount of research being generated.*" She continued: "*We would like to thank our Senior Editors and Editorial Boards for their hard work, intellectual input and guidance in targeting and evaluating topical, pioneering content to ensure inclusion of the journals by MEDLINE.*"

FREE TRIAL ACCESS

Access to both journals is available on a **FREE** 30-day trial basis. To apply for your free trial to *Pharmaceutical Patent Analyst* please email info@future-science.com quoting reference **PPA2013** to obtain password access; or for *Journal of Comparative Research Effectiveness*, please email info@futuremedicine.com quoting CER2013.

-- ENDS --

NOTES FOR EDITORS

ABOUT FUTURE SCIENCE GROUP

The Future Science Group (www.future-science-group.com) is an expanding group of independent publishing companies active in the field of scientific information and endeavour, including **Future Medicine Ltd** and **Future Science Ltd**. As a leading provider of products and services for the medical, science and business communities, we present the most important scientific breakthroughs in an accessible and evaluated format, while at the same time providing the scientific community with unique vehicles for disseminating forward-thinking research information and data. Complete listings of titles under each imprint are available at www.futuremedicine.com and www.future-science.com.

ABOUT PHARMACEUTICAL PATENT ANALYST

Pharmaceutical Patent Analyst is unique publication primarily dedicated to publishing rigorous scientific review articles discussing recent patents of relevance to pharmaceutical and medical R&D. Indexing: Chemical Abstracts and EMBASE/Excerpta Medica, Pubmed/MEDLINE.

Coverage:

Analyses of the patent literature:

Reviews examining patents of relevance to all therapeutic areas are accepted, including:

- Chemical and biological entities of therapeutic significance
- Healthcare products (e.g., medical devices and drug-delivery systems)
- Drug-discovery and design technologies
- Inventions in related disciplines (e.g., biotechnology and nanotechnology)

Articles dedicated the following are also considered:

- Analyses of patenting trends for selected patent classes, therapeutic areas or geographic regions
- Design and application of novel methodologies for searching and analysing the patent literature

Commentary on IP issues:

- Perspectives and analysis on IP/patent law issues of importance to the patent lifecycle, or to pharmaceutical and medical R&D more broadly.

ABOUT JOURNAL OF COMPARATIVE RESEARCH EFFECTIVENESS

Healthcare is at a turning point. We have entered a new era of high patient expectations, aging populations and socioeconomic constraints. At the same time, attention is focusing more closely on personalized approaches to healthcare delivery, and healthcare options, especially in fields such as oncology, are proliferating. There is now a pressing need to make direct comparisons between the available healthcare options and interventions in order to address uncertainties in optimal clinical practice.

In this new environment, the goal of comparative effectiveness research (CER) is to assist patients, physicians, purchasers, and policy makers to choose between the available effective treatments in order to improve healthcare delivery at the level of the individual and on a population scale. The underlying question in undertaking comparative effectiveness research is - which treatment will work best, in which patient, and under what circumstances?

Against this backdrop, the peer-reviewed bimonthly *Journal of Comparative Effectiveness Research* provides a rapid-publication platform for debate and for the presentation of new findings.

Articles published in *Journal of Comparative Effectiveness Research* cover key areas such as:

- Studies of effectiveness or comparative effectiveness yielding new findings relating to diagnostics, therapeutics, surgical procedures, or other healthcare services or options
- Systematic reviews of available evidence relating to the pros and cons of healthcare options for specific patient groups including comparative safety
- Perspectives and debate relating to the performance of comparative effectiveness studies and best practice issues

- Commentary on both patient-relevant outcomes and economic implications
- Direct 'head-to-head' comparisons of available diagnostic and therapeutic options – evaluating clinical alternatives with current standard of care
- Clinical trial commentaries – evaluating and interpreting the findings of recently completed CER trials as well as presenting the design and rationale of newly commenced studies
- Pharmacoeconomic studies, health economics and outcomes research

Through rigorous evaluation and comprehensive coverage, the *Journal of Comparative Effectiveness Research* provides stakeholders (including patients, clinicians, healthcare purchasers, and health policy makers) with the key data and opinions to make informed and specific decisions on clinical practice.